The Immunology Innovation Program at argenx is dedicated to discovering and developing novel antibody-based therapies for a wide range of autoimmune diseases. This segment focuses on leveraging the company's proprietary technologies, including the SIMPLE Antibody™ platform, to generate differentiated therapeutic candidates. Research and development efforts encompass target identification, antibody engineering, preclinical studies, and early-stage clinical trials. The program aims to address unmet medical needs in areas such as myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and other severe autoimmune conditions. By advancing innovative immunology research, argenx seeks to improve patient outcomes and establish a leading position in the autoimmune disease market. Partnerships and collaborations with academic institutions and other biotechnology companies are integral to this segment's success.

This business segment focuses on the development of cusatuzumab and other antibody-based therapies for the treatment of hematological cancers, including high-risk myelodysplastic syndromes (MDS). Research and development activities involve preclinical studies, clinical trials, and biomarker discovery to identify patient populations most likely to benefit from these therapies. The segment leverages argenx's antibody engineering capabilities to create targeted treatments that enhance immune responses against cancer cells. By addressing the unmet needs in hematological malignancies, argenx aims to improve patient survival rates and quality of life. Strategic collaborations with other pharmaceutical companies and research institutions are essential for advancing the clinical development and commercialization of these innovative cancer therapies. The focus is on developing therapies that offer improved efficacy and reduced toxicity compared to existing treatments.